StimLabs

StimLabs is a regenerative medicine company founded in 2015, focused on enhancing patient care through innovative and personalized solutions. The company specializes in developing advanced regenerative products, particularly placental-derived allografts and extracellular matrix devices, aimed at restoring the body’s natural form and function. StimLabs offers a diverse product portfolio that includes a porcine-derived advanced wound matrix for office-based advanced wound care and a dehydrated human umbilical cord particulate device for surgical and wound care applications. Other products include dehydrated human placental membrane allografts, which are utilized in spinal fusion surgeries and reconstructive procedures. The company is committed to supporting healthcare providers and patients with education, billing, and reimbursement assistance. With a strong intellectual property portfolio and a focus on quality and innovation, StimLabs aims to be a trusted leader in regenerative medicine, serving physicians and healthcare providers in fields such as general surgery, dermatology, and wound care.

• Employees 240
• Founded 2015
• Annual Revenue $68500000
• Total Funding $10000000